Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX)

CAPS Rating: 2 out of 5

A biopharmaceutical company focusing on the development and commercialization of innovative therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases.

Recs

0
Player Avatar OklaBoston (67.43) Submitted: 1/13/2013 12:45:12 PM : Outperform Start Price: $2.68 PGNX Score: +21.66

Insider trade and freedom from debt outweigh the TTM losses in my book.

Featured Broker Partners


Advertisement